EyeGate's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis

Marketwired
EyeGate's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis
EyeGate Pharma Logo
View Comments (0)